Postmenopausal Vaginal Atrophy Drugs Market

The global Postmenopausal Vaginal Atrophy Drugs market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Topical Estrogen Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Postmenopausal Vaginal Atrophy Drugs include Pfizer Inc, Mylan NV, Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc, Melinta Therapeutics, Inc, Bristol-Myers Squibb Company and GSK plc, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Postmenopausal vaginal atrophy (PVA) is the type of condition of vaginal wall thinning the reduced level of estrogen causes that. The changes in the genitourinary tract arising from a hypoestrogenic state includes decreased vaginal vascularization, reduced vaginal lubrication, thinning of the vaginal epithelium. The pH level continuously increases and loss of lactobacilli microflora allows opportunistic colonization by pathogenic bacteria can produce infection.
Postmenopausal Vaginal Atrophy Drugs Market aims to provide a comprehensive presentation of the global market for Postmenopausal Vaginal Atrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Postmenopausal Vaginal Atrophy Drugs. Postmenopausal Vaginal Atrophy Drugs Market contains market size and forecasts of Postmenopausal Vaginal Atrophy Drugs in global, including the following market information:
Global Postmenopausal Vaginal Atrophy Drugs Market Revenue, 2020-2024, 2025-2030, ($ millions)
Global Postmenopausal Vaginal Atrophy Drugs Market Sales, 2020-2024, 2025-2030, (K Units)
Global top five Postmenopausal Vaginal Atrophy Drugs companies in 2023 (%)
We surveyed the Postmenopausal Vaginal Atrophy Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Postmenopausal Vaginal Atrophy Drugs Market, by Type, 2020-2024, 2025-2030 ($ Millions) & (K Units)
Global Postmenopausal Vaginal Atrophy Drugs Market Segment Percentages, by Type, 2023 (%)
Topical Estrogen
Oral Estrogen
Other
Global Postmenopausal Vaginal Atrophy Drugs Market, by Application, 2020-2024, 2025-2030 ($ Millions) & (K Units)
Global Postmenopausal Vaginal Atrophy Drugs Market Segment Percentages, by Application, 2023 (%)
Online Pharmacy
Hospital Pharmacy
Global Postmenopausal Vaginal Atrophy Drugs Market, By Region and Country, 2020-2024, 2025-2030 ($ Millions) & (K Units)
Global Postmenopausal Vaginal Atrophy Drugs Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Postmenopausal Vaginal Atrophy Drugs revenues in global market, 2020-2024 (Estimated), ($ millions)
Key companies Postmenopausal Vaginal Atrophy Drugs revenues share in global market, 2023 (%)
Key companies Postmenopausal Vaginal Atrophy Drugs sales in global market, 2020-2024 (Estimated), (K Units)
Key companies Postmenopausal Vaginal Atrophy Drugs sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer Inc
Mylan NV
Novartis AG
Hikma Pharmaceuticals plc
Aurobindo Pharma
AbbVie Inc
Melinta Therapeutics, Inc
Bristol-Myers Squibb Company
GSK plc
Bayer AG
Lupin
Perrigo Company plc
Bionovo, Inc
TherapeuticsMD, Inc
Endoceutics, Inc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Postmenopausal Vaginal Atrophy Drugs, market overview.
Chapter 2: Global Postmenopausal Vaginal Atrophy Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Postmenopausal Vaginal Atrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Postmenopausal Vaginal Atrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Postmenopausal Vaginal Atrophy Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.